Consequently, TNFR2 has emerged as a promising therapeutic target, with current translational research efforts focused on developing biologics and small molecules to modulate TNFR2 activity in autoimmune diseases, GVHD, and cancer. Here, TNFRSF1B is linked to graft versus host disease.